Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
J Glob Antimicrob Resist ; 25: 199-201, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-33812048

RESUMEN

OBJECTIVES: Candida tropicalis is one of the three most frequent species causing candidaemia in Latin America. Despite the high prevalence of C. tropicalis in candidaemia cases in Brazil, little is known about the trends in fluconazole susceptibility over time. The objective of this study was to evaluate temporal trends in azole resistance rates among C. tropicalis bloodstream isolates from patients treated in six Brazilian medical centres over a 12-year period. METHODS: We selected 200 C. tropicalis bloodstream isolates from six medical centres in Brazil collected between 2007 and 2018. Species identification was confirmed by MALDI-TOF/MS. Antifungal susceptibility testing for four antifungal agents was performed by the Clinical and Laboratory Standards Institute (CLSI) microbroth method. RESULTS: Overall, rates of non-susceptibility were 4% and 3.5% to fluconazole and voriconazole, respectively. All isolates were susceptible to amphotericin B and only one isolate was resistant to echinocandins. CONCLUSION: Although we failed to demonstrate statistical differences in the rates of azole resistance documented during the period of analysis, trends towards lower susceptibility to fluconazole and voriconazole were shown.


Asunto(s)
Azoles , Candida tropicalis , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Azoles/farmacología , Brasil , Candida , Farmacorresistencia Fúngica , Humanos , Pruebas de Sensibilidad Microbiana
2.
Mycopathologia ; 185(4): 685-690, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32524348

RESUMEN

Despite advances in fungal diagnostics and antifungal therapy, mortality associated with candidaemia remains very high, particularly in developing countries. In this study, we reviewed the Brazilian literature on candidaemia over the last 20 years (1999-2019), with the aim to document if mortality rates changed over the years in Brazil. Variables studied included number of patients with candidaemia per study, age, most prevalent Candida species and use of antifungals. Selected manuscripts evaluated a median of 114 patients, the majority being men (54.4%). Median age was 45 year-old. The most prevalent species in all studies was C. albicans (37.3%), followed by C. parapsilosis (23.0%). An increase in use of echinocandins occurred in recent years, with a proportional decrease in the use of fluconazole and amphotericin B. Surprisingly, mortality of candidaemia has remained unchanged over the years in the largest Latin American country, regardless of treatment with echinocandins. Potential explanations for these findings are discussed.


Asunto(s)
Candidemia/mortalidad , Antifúngicos/uso terapéutico , Brasil/epidemiología , Candida , Candidemia/tratamiento farmacológico , Equinocandinas , Femenino , Fluconazol , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad
3.
Mycoses ; 63(8): 812-822, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32428294

RESUMEN

BACKGROUND: Invasive fungal disease is a significant cause of morbidity and mortality in immunosuppressed children. The recognition of patients at risk for candidaemia is paramount to a better prognosis. OBJECTIVES: To characterize Candida spp bloodstream infections (BSI) in a reference centre for paediatric oncology and to describe the most prevalent risk factors associated with candida infections. PATIENTS/METHODS: This is a retrospective cohort study carried out with paediatric patients followed up with at the Institute of Pediatric Oncology, Brazil, who presented positive blood culture for Candida spp from January 2004 to December 2016. RESULTS: Ninety episodes of candidaemia were analysed; patients had a median age of 4.5 years, and 57.8% were males, with a diagnosis of solid tumours in 54.5% of cases. The most common Candida species were C albicans (35.6%), C parapsilosis (30.0%) and C tropicalis (16.7%). C tropicalis BSI was associated with neutropenia and skin lesions. Therapy was successful in 67.1% of the episodes. Older age and thrombocytopenia were associated with therapeutic failure. Death within 30 days occurred in 24.4% of patients; predictive factors were older age and admission to an ICU C parapsilosis candidaemia was a protective factor for death when compared to C albicans. CONCLUSION: The main species isolated were C albicans, C parapsilosis and C tropicalis. C tropicalis BSI was associated with neutropenia and skin lesions. The death rate was significant, and a worse prognosis was associated with older age, thrombocytopenia and admission to an ICU C parapsilosis infection proved to be a protective factor against mortality.


Asunto(s)
Candidemia , Adolescente , Factores de Edad , Brasil/epidemiología , Candida/aislamiento & purificación , Candidemia/diagnóstico , Candidemia/epidemiología , Candidiasis/diagnóstico , Niño , Preescolar , Femenino , Humanos , Terapia de Inmunosupresión , Lactante , Unidades de Cuidados Intensivos , Infecciones Fúngicas Invasoras/diagnóstico , Masculino , Oncología Médica , Mortalidad , Neoplasias/complicaciones , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Sepsis/diagnóstico , Trombocitopenia
4.
J Glob Antimicrob Resist ; 13: 254-260, 2018 06.
Artículo en Inglés | MEDLINE | ID: mdl-29183771

RESUMEN

OBJECTIVES: Invasive candidiasis has a high impact on morbidity and mortality in hospitalised patients. Accurate and timely methods for identification of Candida spp. and determination of echinocandin susceptibility have become a priority for clinical microbiology laboratories. METHODS: This study was performed to compare matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF/MS) identification with sequencing of the D1/D2 region of the rRNA gene complex 28 subunit in 147 Candida spp. isolates obtained from patients with candidaemia. Antimicrobial susceptibility testing was performed by broth microdilution (BMD) and Etest. Sequencing of the FKS1 and FKS2 genes was performed. RESULTS: The most common species isolated were Candida albicans (40.8%), followed by Candida parapsilosis (23.1%) and Candida tropicalis (17.0%). Overall agreement between the results of identification by MALDI-TOF/MS and molecular identification was 99.3%. Anidulafungin and caspofungin susceptibility by the BMD method was 98.0% and 88.4%, respectively. Susceptibility to anidulafungin and caspofungin by Etest was 93.9% and 98.6%, respectively. Categorical agreement between Etest and BMD was 91.8% for anidulafungin and 89.8% for caspofungin, with lower agreements in C. parapsilosis for anidulafungin (76.5%) and C. glabrata for caspofungin (40.0%). No mutations related to resistance were found in the FKS genes, although 54 isolates presented synonymous polymorphisms in the hotspots sequenced. CONCLUSIONS: MALDI-TOF/MS is a good alternative for routine identification of Candida spp. isolates. DNA sequencing of the FKS genes suggested that the isolates analysed were susceptible to echinocandins; alternatively, unknown resistance mechanisms or limitations related to antifungal susceptibility tests may explain the resistance found in a few isolates.


Asunto(s)
Antifúngicos/farmacología , Candida/efectos de los fármacos , Candida/genética , Candidemia/epidemiología , Equinocandinas/farmacología , Anidulafungina/farmacología , Cultivo de Sangre , Candida/aislamiento & purificación , Caspofungina/farmacología , Colombia , Pruebas Antimicrobianas de Difusión por Disco , Genes de ARNr , Secuenciación de Nucleótidos de Alto Rendimiento , Hospitales/estadística & datos numéricos , Humanos , Pruebas de Sensibilidad Microbiana , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción
5.
Clin Microbiol Infect ; 24(3): 246-250, 2018 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-28847765

RESUMEN

BACKGROUND: Neutropenic patients developing acute disseminated candidiasis may present with skin lesions. AIMS: To evaluate the epidemiology of acute disseminated candidiasis with skin lesions in neutropenic patients, taking into consideration changes caused by different prophylactic strategies. SOURCES: A systematic review of English-language articles found via PubMed (1963-2016) was performed. We asked the following questions: (a) What Candida species are more frequently involved in this syndrome? (b) Has antifungal prophylaxis changed the species causing skin lesions? (c) What are the typical patterns of skin lesions? (d) What is the frequency of skin lesions in neutropenic patients with candidaemia or acute disseminated candidiasis? (e) Has antifungal prophylaxis decreased the incidence of acute disseminated candidiasis with skin lesions? CONTENT: Among 183 studies, 33 were selected, reporting 100 cases of acute disseminated candidiasis with skin lesions in neutropenic patients. It occurred more frequently in the setting of induction therapy for de novo or relapsed acute leukaemia, and the most frequent Candida species were C. tropicalis (68%) and C. krusei (15%). Diffuse maculopapular lesions predominated in cases caused by C. tropicalis and nodular and papular lesions in cases caused by C. krusei. Prophylaxis with fluconazole was reported in six cases, C. krusei in five and C. ciferrii in one. The death rate was 45.4%. IMPLICATIONS: Two patterns were recognized: disseminated maculopapular lesions caused by C. tropicalis in patients not receiving fluconazole prophylaxis, occurring in 39% to 44% of neutropenic patients with acute disseminated candidiasis, and nodular lesions caused by C. krusei in patients receiving fluconazole prophylaxis, occurring less frequently.


Asunto(s)
Candida/clasificación , Candida/aislamiento & purificación , Candidiasis Invasiva/patología , Neutropenia/complicaciones , Piel/patología , Antifúngicos/administración & dosificación , Candidiasis Invasiva/epidemiología , Candidiasis Invasiva/prevención & control , Quimioprevención/estadística & datos numéricos , Humanos , Huésped Inmunocomprometido
6.
Rev Iberoam Micol ; 34(3): 165-170, 2017.
Artículo en Español | MEDLINE | ID: mdl-28457646

RESUMEN

BACKGROUND: Candida parapsilosis is a species complex consisting of Candida parapsilosis sensu stricto, Candida orthopsilosis, and Candida metapsilosis. Studies worldwide have described its epidemiology and susceptibility to antifungal agents. AIMS: The aims of this study were to carry out the molecular identification of blood isolates belonging to the Candida parapsilosis species complex, and to determine their in vitro susceptibility to antifungals of systemic use. METHODS: A study of 86 strains of C. parapsilosis species complex collected in 2008-2011 and obtained from the Candidaemia Surveillance Network of Mycology Department of the Rafael Rangel National Institute of Hygiene, was made. Secondary alcohol-dehydrogenase gene amplification was performed using polymerase chain reaction, and the products were analysed by restriction fragments length polymorphisms using the enzyme BanI. Susceptibility tests were performed using Etest®, following the manufacturer's instructions with modifications. RESULTS: Of the 86 isolates studied, 81 (94.2%) were C. parapsilosis sensu stricto, 4 (4.6%) C. orthopsilosis, and one (1.2%) C. metapsilosis. C. parapsilosis isolates were susceptible to amphotericin B and caspofungin, showing low rates of resistance to fluconazole and voriconazole. C. orthopsilosis and C. metapsilosis were susceptible to all the antifungals tested. CONCLUSIONS: The results obtained in Venezuela provide for the first time important information about the distribution of C. parapsilosis species complex in cases of candidaemia, and support the need for continuing surveillance programs, including molecular discrimination of species and antifungal susceptibility tests, which may guide specific therapy.

7.
Mem. Inst. Oswaldo Cruz ; 112(3): 214-219, Mar. 2017. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1040568

RESUMEN

Since the description of Candida orthopsilosis and C. metapsilosis in 2005, several methods have been proposed to identify and differentiate these species from C. parapsilosis sensu stricto. Species-specific uniplex polymerase chain reaction (PCR) was performed and compared with sequencing of the D1/D2 region of the LSU 28S rDNA gene, microsatellite typing of C. parapsilosis sensu stricto, and PCR-restriction fragment length polymorphism patterns in the ITS1-5.8S-ITS2 region of the rDNA gene. There was agreement between results of testing of 98 clinical isolates with the four PCR-based methods, with 59 isolates identified as C. parapsilosis sensu stricto, 37 as C. orthopsilosis, and two as C. metapsilosis.


Asunto(s)
Humanos , Candida/aislamiento & purificación , Técnicas de Tipificación Micológica/métodos , Polimorfismo de Longitud del Fragmento de Restricción , Candida/clasificación , Candida/genética , ADN de Hongos/análisis , Reacción en Cadena de la Polimerasa , Dermatoglifia del ADN , Análisis de Secuencia de ADN , ADN Espaciador Ribosómico/genética , Genotipo
8.
Rev Iberoam Micol ; 34(2): 106-108, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28214273

RESUMEN

BACKGROUND: Recent decades have seen a global emergence of candidaemia caused by non-Candida albicans Candida species, particularly the Candida parapsilosis complex. AIMS: To evaluate the clinical features and antifungal susceptibility profiles of isolates belonging to the C. parapsilosis species complex in patients with candidaemia in a midwestern Brazilian tertiary-care teaching hospital. METHODS: Yeast identification was performed using an automated Vitek 2 Compact system. PCR-RFLP was employed for species differentiation. RESULTS: Five cases of infection by C. parapsilosis sensu stricto and two by Candida orthopsilosis were found. Of the seven cases, five were adult patients undergoing haemodialysis. The only isolate of C. parapsilosis sensu stricto resistant to fluconazole (MIC=8µg/ml) was obtained from a patient on a long-term regimen with this drug. This was the only patient who evolved to death. CONCLUSIONS: Resistance to antifungal agents poses a therapeutic challenge, especially for non-C. albicans Candida species, and requires continuous monitoring using susceptibility tests because resistance in vitro can be predictive of treatment failure. In the present study, in vitro antifungal susceptibility proved consistent with clinical outcome.


Asunto(s)
Antifúngicos/farmacología , Candida parapsilosis/aislamiento & purificación , Candidemia/epidemiología , Infección Hospitalaria/epidemiología , Adulto , Anciano , Anfotericina B/farmacología , Antifúngicos/uso terapéutico , Brasil/epidemiología , Candida parapsilosis/efectos de los fármacos , Candidemia/tratamiento farmacológico , Candidemia/microbiología , Preescolar , Infección Hospitalaria/microbiología , Farmacorresistencia Fúngica , Unidades Hospitalarias , Humanos , Lactante , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Técnicas de Tipificación Micológica , Diálisis Renal , Centros de Atención Terciaria , Triazoles/farmacología
9.
Clin Microbiol Infect ; 21(10): 954.e9-17, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26070961

RESUMEN

A retrospective study was conducted to assess the role of initial serum (1,3)-ß-d-glucan (BDG) values in predicting mortality in proven candidaemia. The study was conducted in two large teaching hospitals in Italy and Brazil. From January 2009 to June 2014, all patients with proven candidaemia who underwent a BDG test within 96 hours before or after the first positive blood culture were included in the study. The primary end point was 28-day mortality, with the role of initial BDG being assessed by univariate and multivariate analyses. A total of 104 patients met the inclusion criteria. Overall, the crude 28-day mortality was 30% (31/104). In the final multivariate model, an initial BDG of >287 pg/mL (odds ratio (OR) 4.40, 95% confidence interval (CI) 1.56-12.39, p 0.005), haemodialysis (OR 4.33, 95% CI 1.24-15.17, p 0.022) and a Pitt score of ≥ 2 (OR 4.10, 95% CI 1.24-13.54, p 0.021) were significant predictors of 28-day mortality. The >287 pg/mL cutoff predicted 28-day mortality with 65% sensitivity and 70% specificity. Centre of enrolment (p for interaction 0.012), haemodialysis (p for interaction 0.062) and timing of BDG test of more than 24 hours before or after the positive culture (p for interaction 0.143) appeared to interact with BDG's ability to predict mortality. Although not statistically significant, the last two of these interactions might partially explain why BDG's ability to predict mortality was present only in the Italian cohort.


Asunto(s)
Biomarcadores/sangre , Candidemia/diagnóstico , Candidemia/patología , Técnicas de Apoyo para la Decisión , Suero/química , beta-Glucanos/sangre , Adulto , Anciano , Anciano de 80 o más Años , Brasil , Candidemia/mortalidad , Femenino , Hospitales de Enseñanza , Humanos , Italia , Masculino , Persona de Mediana Edad , Pronóstico , Proteoglicanos , Estudios Retrospectivos , Sensibilidad y Especificidad , Análisis de Supervivencia
10.
Mycoses ; 57(1): 12-8, 2014 01.
Artículo en Inglés | MEDLINE | ID: mdl-23710653

RESUMEN

Incidence and mortality of candidaemia/invasive candidiasis (C/IC) is relatively high in Latin America versus North America and Europe. To assess efficacy and safety of intravenous (IV) anidulafungin in Latin American adults with documented C/IC. All patients in this open-label study received initial IV anidulafungin with optional step-down to oral voriconazole after 5 days; total treatment duration was 14-42 days. The primary endpoint was global response (clinical + microbiological response) at end of treatment (EOT); missing/indeterminate responses were failures. The study enrolled 54 patients; 44 had confirmed C/IC within 96 h before study entry and comprised the modified intent-to-treat population. Global response at EOT was 59.1% (95% CI: 44.6, 73.6), with 13 missing/indeterminate assessments. Thirty-day all-cause mortality was 43.1%. Fourteen patients (31.8%) were able to step-down to oral voriconazole; these patients had lower baseline acute physiological assessment and chronic health evaluation (APACHE) II scores and were less likely to have solid tumours or previous abdominal surgery. Anidulafungin was generally well tolerated with few treatment-related adverse events. Anidulafungin was associated with relatively low response rates influenced by a high rate of missing/indeterminate assessments and mortality comparable to other recent candidaemia studies in Latin America. In a subset of patients with lower APACHE II scores, short-course anidulafungin followed by oral voriconazole was successful.


Asunto(s)
Antifúngicos/administración & dosificación , Candidiasis Invasiva/tratamiento farmacológico , Equinocandinas/administración & dosificación , Pirimidinas/administración & dosificación , Triazoles/administración & dosificación , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anidulafungina , Femenino , Humanos , América Latina , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Voriconazol , Adulto Joven
11.
West Indian med. j ; West Indian med. j;62(8): 724-730, Nov. 2013. tab
Artículo en Inglés | LILACS | ID: biblio-1045741

RESUMEN

OBJECTIVE: Candidaemia is the fourth most common cause of nosocomial bloodstream infections. The objective of this paper was to evaluate the risk factors associated with mortality in patients with candidaemia with respect to Candida species and their susceptibilities, retrospectively. METHODS: All consecutive patients who developed candidaemia at an 800-bed training and research hospital were enrolled in this retrospective, observational, single centre study during the period June 2006 to December 2011. RESULTS: A total of 97 candidaemia episodes were identified in 97 patients during the study period with an overall incidence of four episodes/10 000 admissions in adults. Crude 30-day mortality rates among patients with candidaemia were 56% (55 of 97 cases). Urinary catheterization, immunosuppressive therapy, acute physiology and chronic health evaluation (APACHE) II score (>16) and hypoal-buminaemia were found to be independent risk factors for fatal candidaemia. CONCLUSIONS: Adult cases with candidaemia who have risk factors associated with mortality are more likely to have poor prognosis despite appropriate and timely initiated antifungal drug treatment. Empiric antifungal drug should be tailored according to the severity of the patients ' conditions and local antifungal susceptibility.


OBJETIVO: La candidemia es la cuarta causa más común de infecciones nosocomiales del flujo sanguíneo. El objetivo del presente trabajo fue evaluar los factores de riesgo asociados con la mortalidad en pacientes con candidemia con respecto a las especies de Candida y sus susceptibilidades, de manera retrospectiva. MÉTODOS: Todos los pacientes consecutivos que desarrollaron candidemia en un hospital de capacitación e investigación de 800 camas, fueron inscritos en este estudio retrospectivo, observacional, monocéntrico, durante el período de junio de 2006 a diciembre de 2011. RESULTADOS: Se identificaron un total de 97 episodios de candidemia en 97 pacientes durante el período de estudio con una incidencia general de cuatro episodios/10 000 ingresos en adultos. Las tasas brutas de mortalidad de 30 días entre los pacientes con candidemia fueron 56% (55 de 97 casos). Se halló que la cateterización urinaria, la terapia inmunosupresiva, y la puntuación (> 16) de la escala de Evaluación de la fisiología aguda y salud crónica (APACHE II) así como la hipoalbuminemia, constituyen factores de riesgo para una candidemia fatal. CONCLUSIONES: Los casos adultos con candidemia que tienen factores de riesgo asociados con mortalidad son más propensos a tener un pronóstico pobre a pesar del tratamiento apropiado y oportuno con medicamentos antimicóticos. Los antimicóticos empírico se deben adaptar según la severidad de las condiciones de los pacientes y la susceptibilidad antifúngica local.


Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Adulto Joven , Candida/clasificación , Farmacorresistencia Fúngica Múltiple , Candidemia/microbiología , Candidemia/mortalidad , Candida/efectos de los fármacos , Incidencia , Estudios Retrospectivos , Factores de Riesgo
12.
Mem. Inst. Oswaldo Cruz ; 108(3): 288-292, maio 2013. tab, graf
Artículo en Inglés | LILACS | ID: lil-676979

RESUMEN

Candida species are an important cause of bloodstream infections (BSI). To evaluate the epidemiological, clinical and microbiological aspects of two cohorts {1994-1999 [period 1 (P1) ]; 2000-2004 [period 2 (P2) ]} of candidaemic patients, we performed a retrospective analysis from a laboratory-based survey. A total of 388 candidaemias were identified, with an incidence of 0.20/1,000 patient-days and a significant increase in P2 vs. P1 (0.25 vs. 0.15, p = 0.04). Cancer and prior antibiotic use were frequent and Candida albicans was the most prevalent species found (42.4%). Resistance to fluconazole was found in 2.47% of the strains. No differences were observed in the species distribution of Candida during the study periods. In the P2 cohort, there were higher prevalence of elderly individuals, cardiac, pulmonary and liver diseases, renal failure, central venous catheters and antibiotic therapy. In P1, there were higher prevalence of neurological diseases and chemotherapy. The crude mortality was 55.4%. In conclusion, our incidence rates remained high. Furthermore, the distribution pattern of Candida species and the fluconazole resistance profile remained unchanged. Moreover, we found a clear trend of higher prevalence of candidaemia among the elderly and among patients with comorbidities. Finally, it is necessary to discuss strategies for the prevention and control of Candida BSI in Brazil.


Asunto(s)
Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Adulto Joven , Candidemia/epidemiología , Brasil/epidemiología , Candidemia/microbiología , Incidencia , Estudios Retrospectivos , Centros de Atención Terciaria/estadística & datos numéricos
13.
Braz. j. microbiol ; Braz. j. microbiol;40(2): 321-324, Apr.-June 2009. ilus, tab
Artículo en Inglés | LILACS | ID: lil-520237

RESUMEN

Fungi are common causes of infection in immunocompromised patients. Candida species are frequently involved in these cases. In order to investigate candidiasis in pediatric patients with cancer, clinical samples were collected from one hundred and twenty two patients interned in the Oswaldo Cruz University Hospital in Recife, Brazil. Yeasts were isolated from thirty-four clinical samples. The species isolated were: Candida albicans (fourteen isolates), C. parapsilosis (nine isolates), C. guilliermondii (two isolates) and C. tropicalis (two isolates). We found that candidemia was most frequent in patients with malignant hematology and that C. parapsilosis infections caused the highest mortality.


Os fungos são causas comuns de infecções em pacientes imunocomprometidos e espécies de Candida são freqüentemente envolvidas nesses casos. A fim de investigar infecção fúngica em pacientes pediátricos com câncer, amostras clínicas foram coletadas de cento e vinte dois pacientes internados no Hospital Universitário Oswaldo Cruz em Recife, Brasil. Leveduras foram isoladas de trinta e quatro amostras clínicas. As leveduras isoladas foram: Candida albicans (catorze isolados), C. parapsilosis (nove isolados), C. guilliermondii (dois isolados) e C. tropicalis (dois isolados). Descobrimos que candidemia foi mais freqüente em doentes com hematologias malignas e que C. parapsilosis apresentou maior mortalidade.


Asunto(s)
Humanos , Niño , Candidiasis , Hematología , Levaduras/aislamiento & purificación , Micosis , Neoplasias , Técnicas y Procedimientos Diagnósticos , Hospitales , Métodos , Pacientes , Métodos
14.
Braz J Microbiol ; 40(2): 321-4, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24031365

RESUMEN

Fungi are common causes of infection in immunocompromised patients. Candida species are frequently involved in these cases. In order to investigate candidiasis in pediatric patients with cancer, clinical samples were collected from one hundred and twenty two patients interned in the Oswaldo Cruz University Hospital in Recife, Brazil. Yeasts were isolated from thirty-four clinical samples. The species isolated were: Candida albicans (fourteen isolates), C. parapsilosis (nine isolates), C. guilliermondii (two isolates) and C. tropicalis (two isolates). We found that candidemia was most frequent in patients with malignant hematology and that C. parapsilosis infections caused the highest mortality.

15.
Artículo en Inglés | VETINDEX | ID: vti-444386

RESUMEN

Fungi are common causes of infection in immunocompromised patients. Candida species are frequently involved in these cases. In order to investigate candidiasis in pediatric patients with cancer, clinical samples were collected from one hundred and twenty two patients interned in the Oswaldo Cruz University Hospital in Recife, Brazil. Yeasts were isolated from thirty-four clinical samples. The species isolated were: Candida albicans (fourteen isolates), C. parapsilosis (nine isolates), C. guilliermondii (two isolates) and C. tropicalis (two isolates). We found that candidemia was most frequent in patients with malignant hematology and that C. parapsilosis infections caused the highest mortality.


Os fungos são causas comuns de infecções em pacientes imunocomprometidos e espécies de Candida são freqüentemente envolvidas nesses casos. A fim de investigar infecção fúngica em pacientes pediátricos com câncer, amostras clínicas foram coletadas de cento e vinte dois pacientes internados no Hospital Universitário Oswaldo Cruz em Recife, Brasil. Leveduras foram isoladas de trinta e quatro amostras clínicas. As leveduras isoladas foram: Candida albicans (catorze isolados), C. parapsilosis (nove isolados), C. guilliermondii (dois isolados) e C. tropicalis (dois isolados). Descobrimos que candidemia foi mais freqüente em doentes com hematologias malignas e que C. parapsilosis apresentou maior mortalidade.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA